1 Coronaviruses (CoVs) and low-pathogenicity influenza A viruses (LP IAVs) depend on 2 target cell proteases to cleave their viral glycoproteins and prime them for virus-cell 3 membrane fusion. Several proteases cluster into tetraspanin-enriched microdomains 4 (TEMs), suggesting that TEMs are preferred virus entry portals. Here we found that 5 several CoV receptors and virus-priming proteases were indeed present in TEMs. Isolated 6 TEMs, when mixed with CoV and LP IAV pseudo-particles, cleaved viral fusion proteins to 7 fusion-primed fragments and potentiated viral transductions. That entering viruses utilize 8
enveloped viruses, these proteases are known to reside on target cell surfaces. This 23 research focuses on corona-and influenza A-virus-cell entry, and identifies TEMs as sites 24 of viral proteolysis, thereby defining subcellular locations of virus priming with greater 25 precision. Implications of these findings extend to the use of virus entry antagonists, such 26 as protease inhibitors, which might be most effective when localized to these 27 microdomains.
28

INTRODUCTION
29
Enveloped viruses require fusion with host cell membranes to deliver viral genetic 30 material and initiate infection. This process is catalyzed by fusion glycoproteins, which 31 project from virion membranes and operate by bringing virion and host cell membranes 32 into proximity, ultimately stimulating their coalescence. Amongst the host cell factors 33 required for this membrane fusion are receptors and proteases. Receptors tether viruses 34 to host cell membranes and proteases cleave fusion protein precursors to form the 35 domains that catalyze membrane melding. This proteolytic step is termed "priming", and 36 depending on the virus type, may take place in virus-producing cells (1), in extracellular 37 environments (2), or in virus-target cells (3). Notably, several protease inhibitors prevent 38 viral fusion protein cleavages, and as such, are antiviral agents (4). 39 For many respiratory viruses, including several coronaviruses (CoVs) and low 40 pathogenic (LP) influenza A viruses (IAVs), the relevant priming proteases operate in virus-41 target cells. These proteases cleave the virion glycoproteins mediating receptor binding Respiratory Syndrome (SARS)-CoV (6, 7) and Middle East Respiratory Syndrome (MERS)- 48 CoV (8, 9) . Without TMPRSS2, target cells are significantly less sensitive to these CoVs (8, 49 10), but they are not entirely CoV-resistant, as other host proteases, i.e., cathepsins, can 50 provide for some priming (11, 12) . TMPRSS2 and the TTSP human airway trypsin-like 51 (HAT) protease are also sufficient to prime LP IAV, both in vitro (13) and in vivo (14) . As 52 there is no evidence for cathepsin priming of IAVs, cell-surface proteases may be strictly 53 required to prime LP IAV (15) . 54 The requirement for TTSP-mediated proteolytic processing of CoV and LP IAV 55 glycoproteins is established, but the subcellular location of these cleavage events is not well 56 understood. If these proteases operate during virus entry, then it is likely that target-cell 57 virus receptors would co-reside with priming proteases to make virus priming feasible (7) . 58 One possible location for this co-residence is within tetraspanin-enriched microdomains 59 (TEMs) . TEMs are comprised of homo-and hetero-typic assemblies of tetraspanins, so 60 named for their four-transmembrane spanning architectures. In TEMs, the tetraspanins 61 form a locally-ordered, largely plasma membrane-embedded platform in which projecting 62 integral-membrane adhesion receptors and enzymes are interspersed. As dynamically 63 organized membrane protein complexes, TEMs function to modulate cell adhesion, 64 migration and differentiation (16, 17) as well as pathogen invasion (18). 65 5 There is some modest support for the hypothesis that CoV and LP IAV receptors and 66 proteases are concentrated in TEMs, and that priming of these viruses is therefore highly 67 localized. First, TEMs contain CoV receptors dipeptidyl-peptidase 4 (DPP4) (19) and 68 aminopeptidase N (APN) (20) , and also contain sialic acids (21), the receptors for IAVs. 69 Second, TEMs contain a variety of integral membrane proteases (22) . Third, IAV cell entry 70 is both preferentially observed at CD81 tetraspanin-enriched endosomal locations (23) and 71 reduced by CD81 depletion (24) . 72 Since some CoV receptors interact with tetraspanins, and since LP IAV infection was 73 reduced by tetraspanin CD81 knockdown, we used both CoVs and IAVs to address the 74 importance of TEMs in cell entry. We evaluated the effects of tetraspanin antibodies and 75 individual CD9 tetraspanin depletion on virus-cell entry. We isolated TEMs and analyzed 76 them for the presence of virus receptors and virus-priming proteases. We used the isolated 77 TEMs to extracellularly prime CoVs and IAVs. Our findings supported the hypothesis that 78 these enveloped viruses enter cells through TEMs because these microdomains harbor 79 both virus receptors and virus-priming proteases. (25) OriGene. pCAGGS-TMPRSS2-FLAG and pCAGGS-TMPRSS2-S441A-FLAG were previously 100 constructed (7). TMPRSS11D (HAT) was obtained from Open Biosystems and cloned into 101 pCAGGS between SacI and XhoI restriction sites. pCMVSport6-human CD9 was purchased 102 from Open Biosystems. CD9 and scramble control shRNA constructs flanked by the U6 103 promoter and a RNA Polymerase III stop sequence were engineered into the pUC57 vector 104 by Genescript. The pNL4.3-HIVluc plasmid was provided by the NIH AIDS Research and pCDNA3.1-hDPP4 along with 1 µg/10 6 cells of the indicated shRNA plasmid or a pUC57 141 construct lacking the shRNA. Stable transfectants were selected in DMEM-10% FBS 142 containing 1.2 mg/mL of G418 (Thermo Scientific), for the neomycin resistance on the 143 DPP4 plasmid. Cells underwent selection for at least 7 days before being used in assays.
80
MATERIALS AND METHODS
81
Cells. Human embryonic kidney HEK cells 293T and 293β5
144
Infection in the presence of tetraspanin antibodies. DBT cells or 293β5 cells were 145 transfected with appropriate plasmids encoding viral receptors or proteases, divided into 146 96-well cluster plates, and incubated for 30 min at 37 o C with indicated antibodies, at 0.12 147 µg/µl (~10 7 antibodies / cell). Indicated viruses were then added for 2 h at 37 o C, then cells 148 were rinsed, incubated at 37 o C for 6 h (MHV and PR8), 16 h (VSV), or 48 h (HIV). For PR8, 149 cells were not lysed, and media were analyzed for secreted Gluc. For the other viruses, 150 cells were lysed in passive lysis buffer (Promega). Luciferase levels in media or lysates 151 9 were measured after addition of either Fluc substrate (Promega) or Gluc substrate (New 152 England Biolabs) using a Veritas microplate luminometer (Turner BioSystems).
153
Flow Cytometry. To measure antibody binding, 293β5 cells were lifted with Accutase 154 (Millipore), pelleted and resuspended to 10 6 cells/ml in phosphate buffered saline (PBS) 155 supplemented with 2% FBS containing indicated antibodies at 0.12 µg/µl. After 30 min at 156 37 o C, cells were rinsed thrice by pelleting and resuspension in PBS-2% FBS, then incubated 157 for 30 min at 4 o C with AlexaFluour 488 -conjugated donkey-anti-mouse IgG. After 158 sequential rinsing, cell fluorescence was detected using a BD C6 Accuri flow cytometer. To 159 measure HIV pp binding, 293β5 cells, transfected with empty pCMV6 or with pCMV6-160 Entry-hDPP4, were suspended in PBS-2% FBS. Cells were divided and aliquots were 161 incubated for 30 min at 37 o C with tetraspanin antibodies at 0.12 µg/µl. Cells were chilled, Immunofluorescence microscopy. 293β5 cells were transfected with indicated plasmid 173 DNAs, incubated for two days, and then cooled to room temperature (RT). Antibodies and 174 HIV-mCherry pps were added, cells incubated for 30 min at RT, 10 min at 37 o C, then 175 returned to RT. AlexaFlour -conjugated secondary antibodies were applied for 10 min at 176 RT, along with Hoechst 33258 (Molecular Probes). Cells were rinsed with PBS, fixed with 210 Tetraspanins facilitate the entry of many viruses, including hepatitis C (34), human 211 papilloma (35), and IAV (23). To determine whether entering CoVs also utilize 212 tetraspanins, we evaluated the effects of tetraspanin antibodies on infection by mouse 213 hepatitis virus (MHV) strains A59 and JHM. To this end, murine DBT cells were incubated 214 for 30 min with mouse monoclonal antibodies against the tetraspanins CD9, CD63, CD81, or 215 with an equimolar mixture of the three (αTspan). A monoclonal antibody against 216 transferrin receptor (TfR) was used as an isotype -matched control for general cell coating 217 12 by antibodies. Cells were inoculated with luciferase-expressing recombinant MHV-A59 or -218 JHM for 2 h, then unadsorbed viruses and antibodies were rinsed away. As measured by 219 luciferase levels at 8 hpi, the two viruses were significantly inhibited by all three 220 tetraspanin antibodies, with the antibody combination (αTspan) inhibiting A59 and JHM 221 strains by ~50% and ~90% , respectively (Fig. 1A) . The TfR antibodies did not block the 222 viruses. None of the antibodies interfered with transduction by VSV pps bearing VSV G 223 proteins (VSV pp), indicating that tetraspanin antibodies do not generally suppress virus 224 entry or reporter gene expression. 225 While previous studies have found that CD81 knockdown inhibits IAV entry (23), it 226 is not known whether antibodies to CD81 or other tetraspanins also inhibit IAV infection. 227 Thus we determined whether the tetraspanin antibodies inhibit influenza A/Puerto 228 Rico/8/1934 (H1N1), also known as PR8 IAV. For ease of analysis, we used PR8 containing 229 a Gaussia luciferase (Gluc) reporter gene (29). Many host cells are resistant to PR8 230 infection, because they do not express proteases that prime viral HA proteins (13). 231 Therefore, we transfected 293β5 cells with plasmids encoding HAT or TMPRSS2, then 232 infected with PR8 one day later. HAT will make target cells susceptible to LP-IAV, while 233 TMPRSS2 will not (15). By measuring Gluc accumulations in culture media, we determined 234 that transfecting cells with 0.001 μg/well of HAT was sufficient to render cells susceptible 235 to PR8 infection and that increasing HAT transfection generally led to increased infection 236 ( Fig. 1B ). Knowing this, we determined whether tetraspanin antibodies might block PR8 237 infection of the HAT-expressing cells. Indeed PR8 infection was significantly inhibited by 238 all three tetraspanin antibodies, with the antibody combination (αTspan) effecting ~ 50% 239 blockade. The tetraspanin antibodies did not inhibit VSV pp transductions (Fig. 1C ). The tetraspanin antibodies impaired transductions by all three CoV pps, with MERS 253 pp and SARS pp most notably inhibited ( Fig. 2A ). TfR antibodies did not affect 254 transductions. Using MERS pps, we further determined that tetraspanin antibodies were 255 inhibitory only at the pp entry stage, with no effects on transduction when added 30 min 256 following virus inoculation ( Fig. 2B ). Furthermore, inhibition by the tetraspanin antibodies 257 was not related to the viral particle core, as HIV-based MERS pps were blocked equally to 258 VSV-based MERS pps (data not shown). All of these findings were consistent with 259 inhibition of virus entry at TEMs. and right gold lines). We conclude that the tetraspanin antibodies only modestly interfered 274 with virus binding to cells. 275 These data strongly suggested that tetraspanin antibodies interfere with virus entry 276 after virus-receptor binding. To explain how the antibodies block viruses, we posited that 277 viruses might associate with TEMs after binding to cells, and that the tetraspanin 278 antibodies disrupt some TEM-associated process(es) facilitating virus entry. To determine 279 whether the mCherry MERS pps do indeed appear at TEMs during their cell entry, we 280 incubated chilled 293β5 cells with the fluorescent pps along with tetraspanin CD81 281 antibodies, then shifted to 37 o C for 10 min to permit "patching", i.e., antibody-mediated 282 tetraspanin cross-linking into larger TEM structures (39). Quantitative confocal 283 microscopy revealed that CD81 colocalized with ~20% of MERS pps, but with only ~10% 284 of VSV pps (Fig. 3C, right ). Absence of "bald", i.e. viral glycoprotein-free fluorescent pp 285 15 binding ( Fig. 3C , left) confirmed viral glycoprotein-dependent interactions with cells. 286 Similar, but less compelling co-patching of IAV pp and CD81 were also observed in these 287 experiments (Fig. 3C) . These data indicate that, shortly after binding to cells, some MERS 288 and IAV pp will be present at TEM locations.
RESULTS
209
Tetraspanin antibodies inhibit coronavirus and influenza A virus infections.
289
Proteases eliminate the antiviral activities of tetraspanin antibodies. TEMs are 290 known to contain a variety of cell-surface proteases (22), among which may be one or 291 several CoV and IAV -priming proteases (7, 8, 13, 14) . This led us to hypothesize that in the DBT cell context. We supplied DBT cells with graded doses of TMPRSS2 -encoding 301 plasmids, along with small constant amounts of a GFP reporter plasmid. Following 302 expression, GFP + cells were isolated by FACS, and then used in antibody blockade 303 experiments, as described above. The results indicated that tetraspanin antibodies blocked 304 MHV infection into normal DBT cells ( Fig. 1A and 4A ), but not into DBT cells expressing 305 TMPRSS2 ( Fig. 4A ). Of note, 10 6 cells transfected with 0.004 µg of TMPRSS2 plasmid 306 contained TMPRSS2 protein levels that were far below our western blot and 307 16 immunofluorescent assay detection limits, making it clear that even small amounts of 308 priming proteases nullify the antiviral effects of tetraspanin antibodies (Fig. 4A) . 309 In similar experiments, PR8 and its priming protease HAT were evaluated in entry 310 assays. Here, 293β5 cells were transfected with graded doses of HAT-encoding plasmids, 311 and then infected with PR8, either in the absence or presence of tetraspanin antibodies. 312 The results indicated that HAT bypassed the antibody blockades in a dose-dependent 313 manner (Fig. 4B ). Furthermore, trypsin pre-treated viruses also bypassed the antibody 314 blockades (Fig. 4B, rightmost columns) . Therefore, the hypothesis that proteases mitigate 315 the antiviral activities of tetraspanin antibodies applies to TMPRSS2, HAT and trypsin 316 proteases, and to MHV and PR8 viruses. 317 CD9 knockdown inhibits MERS pp transductions. Antibodies binding to CD9, 318 CD81 and CD63 inhibited CoV (MHV) and IAV (PR8) entry (Fig. 1 ). Amongst these three, 319 CD9 stood out as a candidate for further evaluation, in part because of reports that sperm-320 egg fusion requires CD9 (41) and HIV -induced fusion requires endogenous CD9 levels 321 (42). Therefore, we evaluated how varying CD9 levels might affect susceptibility to the 322 VSV-based MERS pp transductions. We produced 293β5 cells stably expressing hDPP4 and 323 a shRNA against CD9. WB confirmed that these cells expressed hDPP4, but expressed only 324 9% of the CD9 in control cells (Fig. 5A) . Notably, the reduced CD9 did not affect any change (Fig. 6A, upper left) . Streptavidin pulldowns of the isolated HD and LD fractions revealed 355 that all of the detectable cell-surface CD9, CD63, and CD81 were present in the LD material 356 (Fig. 6A, lower left) , indicating that the LD fraction includes the TEMs. Notably, cells lysed 357 by Triton-X 100 (TX-100), a detergent known to solubilize TEMs, also generated an LD 358 fraction that comprised ~20% of plasma membrane proteins (Fig. 6A, upper right) , but was 359 devoid of any cell-surface tetraspanins (Fig. 6A, lower right) . Thus we designated the 360 CHAPS LD subcellular fractions as "TEMs" and the TX-100 LD fractions as "lipid rafts". 361 To determine whether CoV receptors and priming proteases partition into TEMs, it 362 was necessary that 293β5 cells were first transfected to overexpress ACE2, APN, CEACAM 363 (the receptor for MHV (45)), or DPP4. The transfected cells were then lysed in CHAPS, and 364 TEMs isolated by two sequential cycles of floatation on sucrose gradients. Western 365 immunoblotting revealed that ~ 90% of ACE2, APN, and CEACAM and ~ 50% of the DPP4, 366 were partitioned into TEM fractions (Fig. 6B) . Cells overexpressing the virus-priming 367 proteases TMPRSS2 and HAT were similarly fractionated, and roughly 50% of these 368 proteases were found in the TEM fractions (Fig. 6B) . Mature TMPRSS2 and HAT exist as 369 linked cleavage products, and some of the TMPRSS2 and HAT that was not found in TEM was validated by immunofluorescence microscopy. DPP4 and TMPRSS2 were both found 385 near or within CD81-encriched cell-surface puncta (Fig. 7) . Similar partitioning of CD81 386 with a catalytically-inactive mutant TMPRSS2S441A was also observed (Fig. 7) , indicating 387 that enzymatic activity has no effect on subcellular localization. Thus there are 388 recognizable proportions of CoV receptors and priming proteases residing within TEMs.
389
TEMs prime coronaviruses and influenza A viruses for entry.
To determine 390 whether the isolated TEMs have virus-priming activities, we mixed them with MERS pps, 391 inoculated the mixtures onto susceptible target cells and then measured transduction 392 efficiencies. To ensure that the transduction measurements reflected proteolytic priming 393 by the TEMs, and not by endogenous target cell proteases, we suppressed target 293β5-cell 394 priming proteases with leupeptin, a broad-spectrum protease inhibitor. Leupeptin-treated 395 293β5 cells were profoundly resistant to MERS pp transduction (Fig. 8A; top) , indicative of 396 20 requirements for the host proteases. However, MERS pp that were exposed to TEM 397 fractions transduced the leupeptin-treated cells (Fig. 8A, top) , indicating priming. Of note, 398 the bypass of leupeptin was pronounced when MERS pp were exposed to trypsin, or to 399 TEMs containing overexpressed TMPRSS2, but did not reach the levels observed in the 400 absence of leupeptin. In addition, substantial bypass of leupeptin was not achieved by 401 CHAPS HD fractions (data not shown), even though the HD fractions included all soluble 402 proteins as well as ~ 80% of the plasma membrane proteins (Fig. 6A ). These findings 403 indicated that MERS entry-priming activities were greatly concentrated in the TEMs. 404 MERS pp that had been exposed to TEMs were also evaluated to assess the extents 405 of S protein cleavage. Western immunoblots indicated that the TEMs effected cleavage of S 406 proteins, generating proteolytic patterns that were indistinguishable from those generated 407 by trypsin (Fig. 8A; bottom) . The apparent molecular weights of the N-linked glycoprotein 408 products were consistent with cleavages at three multibasic sites, one at 626-629 (RQQR) 409 to create the minor 130 kDa fragment, one at 884-887 (RSAR) to create the major 70 kDa 410 fragment, and one at 1110-1113 (QSKR) to create the minor 40 kDa fragment. The major 411 70 kDa fragment has molecular weight equivalent to the previously documented S2' (1). 412 Analogous experiments were completed with IAV PR8 viruses. In these assays, 413 however, inactivation of host proteases by leupeptin was not required, as PR8 did not 414 respond to endogenous levels of 293-cell proteases. The results of these experiments 415 demonstrated that TEM fractions activated PR8 infectivities, nearly as much as TEMs with 416 overexpressed HAT (Fig. 8B, top) . The fact that the TEMs were isolated from IAV-resistant 417 293β5 cells, yet were capable of priming IAV for infection, are potentially explained by the 418 significant concentration of cell proteases achieved through TEM isolation. As with the MERS S on viral pps, PR8-associated HA proteins were analyzed for 420 cleavage status by western immunoblotting. Here, the TEMs effected cleavage of HA0 into 421 HA1, irrespective of whether HAT was overexpressed and equal to that achieved by trypsin 422 (Fig. 8B; bottom) . Thus the TEM fractions harvested from 293 cells have proteases that 423 cleave and prime both MERS-CoV S and PR8 IAV HA proteins.
424
DISCUSSION
425
We evaluated TEMs for host-cell entry factors and determined that they contain 426 both CoV receptors and transmembrane serine proteases (TMPRs), and were capable of 427 cleaving and priming CoV and IAV fusion proteins. We did not determine whether IAV 428 sialic acid receptors are concentrated in TEMs, but there is evidence of sialylated proteins 429 associating with tetraspanins (21, 48, 49) . The findings suggested that, in natural 430 infections, the CoVs and LP IAVs encounter TEMs during their cell entry, and in doing so 431 become proteolytically primed. This suggestion was consistent with virus entry blockades 432 by tetraspanin antibodies, and with reduced virus entry upon depletion of the tetraspanin 433 CD9. From these results, we have come to the view that TEMs are platforms for several 434 CoV and for LP IAV proteolytic priming events. 435 Previous investigators have hypothesized that TEMs are more flexible or curved 436 than other membrane regions and therefore provide a platform that is more favorable for 437 membrane melding. For example, in mouse oocytes, TEMs facilitate cell membrane 438 wrinkling, which hypothetically lowers the kinetic barrier to fusion with sperm-cell 439 membranes (41). However, in the virus-cell membrane fusions that we have evaluated, it 440 seems that TEMs do not facilitate the membrane fusions per se, but rather facilitate virus 441 22 proteolytic priming. This claim arises in part because tetraspanin antibodies blocked MHV 442 and PR8 infections (Fig. 1) but not when transmembrane protease concentrations were 443 elevated (Fig. 4) . With respect to the mechanisms by which tetraspanin antibodies block 444 virus entry, one possibility is that the bivalent antibodies hold tetraspanins together, 445 rigidifying TEMs and impeding membrane protein movements. Reduced diffusion of virus- CoVs appear to be less restricted in their protease requirements, and members may utilize 457 many or all of the ~19 TMPRs (5), as well as the ~25 membrane metalloproteinases (50). 458 TMPRSS2, however, stands out as a key CoV-priming protease (3, 6-9, 51). Perhaps 459 TMPRSS2 is more promiscuous with substrates than the other TTSPs, although any 460 evidence for this is lacking. Alternatively, TMPRSS2 may act as a "master" protease that 461 cleaves nearby zymogens, activating them in proteolytic cascades (52). Other TMPRSS2-462 activated proteases may then cleave CoV S proteins. In addition, some CoVs may bypass 463 TEM-associated proteases, undergoing cleavage-priming after endocytosis. A key example 464 23 here is with MHV-2, which utilizes endosomal cathepsins to prime S proteins for entry (53) . 465 There is no evidence that cathepsins are localized to TEMs. Thus the requirements for of HAT before being exposed to the same Tspan antibody blockade described in (A). Cells 589 were then infected with PR8-Gluc for 2 h, washed, and secreted Gluc was measured 8 hpi.
590
PR8 viruses pre-treated with trypsin (+Trypsin) were also infected onto cells transfected 591 with 0.001 µg HAT/10 6 cells (rightmost columns). 
